Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Key Documents

View All Documentation

B1170000

Busulfan

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Busulfan, 1,4-Butanediol dimethanesulfonate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule linéaire :
CH3SO2O(CH2)4OSO2CH3
Numéro CAS:
55-98-1
Poids moléculaire :
246.30
Numéro Beilstein :
1791786
Numéro MDL:
MFCD00007562
Code UNSPSC :
41116107
ID de substance PubChem :
329773177
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

busulfan

Fabricant/nom de marque

EDQM

Pf

114-117 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

CS(=O)(=O)OCCCCOS(C)(=O)=O

InChI

1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3

Clé InChI

COVZYZSDYWQREU-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Busulfan EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Pictogrammes

Skull and crossbonesHealth hazard
GHS06,GHS08

Mention d'avertissement

Danger

Mentions de danger

H301,H340,H350,H360FD

Classification des risques

Acute Tox. 3 Oral - Carc. 1A - Muta. 1B - Repr. 1B

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 3

1 of 3

Melphalan powder

Sigma-Aldrich

M2011

Melphalan

5-Fluorouracil ≥99% (HPLC), powder

Sigma-Aldrich

F6627

5-Fluorouracil

Mitomycine C from Streptomyces caespitosus powder, BioReagent, suitable for cell culture

Sigma-Aldrich

M4287

Mitomycine C from Streptomyces caespitosus

Ibrahim El-Serafi et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 913-914, 98-105 (2013-01-05)
Busulphan is an alkylating agent used as conditioning regimen prior to stem cell transplantation. Busulphan is metabolized in the liver and four major metabolites have been identified. The first metabolite is tetrahydrothiophene which is oxidized to tetrahydrothiophene 1-oxide, then sulfolane
Arnon Nagler et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(28), 3549-3556 (2013-08-28)
Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan (Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell transplantation (alloSCT) in adults with acute myelogenous leukemia (AML). Intravenous (IV) Bu has more predictable bioavailability and a
Je-Hwan Lee et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(6), 701-709 (2012-11-07)
We conducted a phase III randomized clinical trial to compare two myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation (HCT) in patients with leukemia and myelodysplastic syndrome. After randomization, 64 patients received busulfan (3.2 mg/kg per day × 4 days)
Edward A Copelan et al.
Blood, 122(24), 3863-3870 (2013-09-26)
Cyclophosphamide combined with total body irradiation (Cy/TBI) or busulfan (BuCy) are the most widely used myeloablative conditioning regimens for allotransplants. Recent data regarding their comparative effectiveness are lacking. We analyzed data from the Center for International Blood and Marrow Transplant
Christopher Bredeson et al.
Blood, 122(24), 3871-3878 (2013-10-02)
We conducted a prospective cohort study testing the noninferiority of survival of ablative intravenous busulfan (IV-BU) vs ablative total body irradiation (TBI)-based regimens in myeloid malignancies. A total of 1483 patients undergoing transplantation for myeloid malignancies (IV-BU, N = 1025;
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique